Abstract
Objectives Autoimmune diseases (ADs) play a significant and intricate role in the onset of cardiovascular diseases (CVDs). Our study aimed to elucidate the shared genetic etiology between Ads and CVDs.
Methods We conducted genome-wide pleiotropy analyses to investigate the genetic foundation comprehensively and shared etiology of six ADs and six CVDs. We analyze the genetic architecture and genetic overlap between these traits. Then, SNP-level functional annotation identified significant genomic risk loci and potential causal variants. Gene-level analyses explored shared pleiotropic genes, followed by pathway enrichment analyses to elucidate underlying biological mechanisms. Finally, we assess potential causal pathways between ADs and CVDs.
Results Despite negligible overall genetic connections, our results revealed a significant genetic overlap between ADs and CVDs, indicating a complex shared genetic architecture spread throughout the genome. The shared loci implicated several genes, including ATXN2, BRAP, SH2B3, ALDH2 (all located at 12q24.11-12), RNF123, MST1R, RBM6, and UBA7 (all located at 3p21.31), all of which are protein-coding genes. Top biological pathways enriched with these shared genes were related to the immune system and intracellular signal transduction.
Conclusions The extensive genetic overlap with mixed effect directions between ADs and CVDs indicates a complex genetic relationship between these diseases. It suggests overlapping genetic risk may contribute to shared pathophysiological and clinical characteristics and may guide clinical treatment and management.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Natural Science Foundation of China Excellent Young Scientists Fund (Overseas) (Grant no. K241141101), National Natural Science Foundation (Grant no. 82470452), Guangdong Basic and Applied Basic Research Foundation for Distinguished Young Scholars (Grant no. 24050000763), Shenzhen Pengcheng Peacock Plan, Shenzhen Basic Research General Projects of Shenzhen Science and Technology Innovation Commission (Grant no. JCYJ20230807093514029) (To Y.F.), Natural Science Foundation of China Excellent Young Scientists Fund (Overseas) (Grant no. K241001101) (To Z.L.), National Natural Science Foundation of China (Grant no. 82300315; 82374240), Guangdong Province Basic and Applied Basic Research Fund Project (Grant no. 2024A1515012174; 2024A1515013184), National Administration of Traditional Chinese Medicine Research Project (Grant no. 0102023703), Project of the State Key Laboratory of Dampness Syndrome of Traditional Chinese Medicine jointly established by the province and the ministry (Grant no. SZ2022KF10), Scientific Research Initiation Project of Guangdong Provincial Hospital of Traditional Chinese Medicine (Grant no. 2021KT1709), Research Project of Guangdong Provincial Bureau of Traditional Chinese Medicine (Grant no. 20241120), Guangdong Provincial Key Laboratory of Research on Emergency in TCM (Grant no. 2023B1212060062; 2023KT15450) (To R.Z.), and Center for Computational Science and Engineering at Southern University of Science and Technology. The funder had no role in the design, implementation, analysis, interpretation of the data, approval of the manuscript, and decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used only openly available GWAS summary statistics on six autoimmune diseases and six CVDs that have originally been conducted using human data. GWAS summary statistics on RA, SLE, T1D, CD, UC, and PSC are available at the GWAS Catalog (GCST90132223, GCST003156, GCST90014023, GCST004132, GCST004133, and GCST004030). GWAS summary statistics on AF, HF, and Stroke are available at the GWAS Catalog (GCST90104539, GCST009541, and GCST90104539). GWAS summary statistics on CAD and PAD are publicly available for download at the Cardiovascular Disease Knowledge Portal (CVDKP) website: https://cvd.hugeamp.org/datasets.html. GWAS summary statistics on VTE are obtained from the deCODE genetics website: https://www.decode.com/summarydata/.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
